Mechanisms of resistance to antibiotics

Current Opinion in Chemical Biology

Volumn 7, Issue 5, 2003, Pages 563-569

  Wright, Gerard D ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; AMINOGLYCOSIDE ANTIBIOTIC AGENT; DALFOPRISTIN; DALFOPRISTIN PLUS QUINUPRISTIN; ENZYME; ERYTHROMYCIN; GLYCOPEPTIDE; KANAMYCIN; LINCOSAMIDE; MACROLIDE; NUCLEIC ACID; ORITAVANCIN; PEPTIDOGLYCAN; PROTEIN; QUINUPRISTIN; RIBOSTAMYCIN; STREPTOGRAMIN; TEICOPLANIN; TELITHROMYCIN; TOBRAMYCIN; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BACTERIOSTASIS; BACTERIUM; CLINICAL TRIAL; CROSS RESISTANCE; CYTOSOL; DRUG DEGRADATION; DRUG EFFECT; DRUG MECHANISM; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TRANSPORT; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; ENZYMATIC DEGRADATION; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MICROORGANISM; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PROTEIN STRUCTURE; PSEUDOMONAS AERUGINOSA; REVIEW; STREPTOCOCCUS PNEUMONIAE;

BACTERIA (MICROORGANISMS); ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS; NEGIBACTERIA; POSIBACTERIA; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE;

EID: 0142168993     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbpa.2003.08.004     Document Type: Review

References (54)

1. The Centers for Disease Control and Prevention. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus - Minnesota and North Dakota, 1997-1999. JAMA 1999, 282:1123-1125.
2. Groom A.V., Wolsey D.H., Naimi T.S., Smith K., Johnson S., Boxrud D., Moore K.A., Cheek J.E. Community-acquired methicillin-resistant Staphylococcus aureus in a rural American Indian community. JAMA. 286:2001;1201-1205.
3. Garau J. Treatment of drug-resistant pneumococcal pneumonia. Lancet Infect Dis. 2:2002;404-415.
4. Loeffler J., Stevens D.A. Antifungal drug resistance. Clin Infect Dis. 36:2003;S31-S41.
5. Whitty C.J., Rowland M., Sanderson F., Mutabingwa T.K. Malaria. BMJ. 325:2002;1221-1224.
6. Griffiths P.D. Resistance in viruses other than HIV. Int J Infect Dis. 6(Suppl 1):2002;S32-S37.
7. Chang S., Sievert D.M., Hageman J.C., Boulton M.L., Tenover F.C., Downes F.P., Shah S., Rudrik J.T., Pupp G.R., Brown W.J.et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med. 348:2003;1342-1347 This report describes the first known strain of clinically acquired high-level resistance to vancomycin in S. aureus and has major implications on the treatment of these infections.
8. Edmond M.B., Wenzel R.P., Pasculle A.W. Vancomycin-resistant Staphylococcus aureus: perspectives on measures needed for control. Ann Intern Med. 124:1996;329-334.
9. Barna J.C.J., Williams D.H. The structure and mode of action of glycopeptide antibiotics. Annu Rev Microbiol. 38:1984;339-357.
10. Pootoolal J., Neu J., Wright G.D. Glycopeptide antibiotic resistance. Annu Rev Pharmacol Toxicol. 42:2002;381-408.
11. Walsh C.T., Fisher S.L., Park I.-S., Prohalad M., Wu Z. Bacterial resistance to vancomycin: five genes and one missing hydrogen bond tell the story. Chem Biol. 3:1996;21-28.
12. Bugg T.D.H., Wright G.D., Dutka-Malen S., Arthur M., Courvalin P., Walsh C.T. Molecular basis for vancomycin resistance in Enterococcus faecium BM4147: biosynthesis of a depsipeptide peptidoglycan precursor by vancomycin resistance proteins VanH and VanA. Biochemistry. 30:1991;10408-10415.
13. Billot-Klein D., Blanot D., Gutmann L., van Heijenoort J. Association constants for the binding of vancomycin and teicoplanin to N-acetyl-D-alanyl-D- alanine and N-acetyl-D-alanyl-D-serine. Biochem J. 304:1994;1021-1022.
14. Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis. 1:2001;147-155.
15. Sieradzki K., Roberts R.B., Haber S.W., Tomasz A. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med. 340:1999;517-523.
16. Hiramatsu K., Hanaki H., Ino T., Yabuta K., Oguri T., Tenover F.C. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother. 40:1997;135-136.
17. Allen N.E., Nicas T.I. Mechanism of action of oritavancin and related glycopeptide antibiotics. FEMS Microbiol Rev. 26:2003;511-532.
18. Ge M., Chen Z., Onishi H.R., Kohler J., Silver L.L., Kerns R., Fukuzawa S., Thompson C., Kahne D. Vancomycin derivatives that inhibit peptidoglycan biosynthesis without binding D-Ala-D-Ala. Science. 284:1999;507-511.
19. Chen L., Walker D., Sun B., Hu Y., Walker S., Kahne D. Vancomycin analogues active against vanA-resistant strains inhibit bacterial transglycosylase without binding substrate. Proc Natl Acad Sci USA. 100:2003;5658-5663 The authors provide compelling evidence for inhibition of transglycosylase required for peptidoglycan assembly as the major target for lipophilic glycopeptide analogues.
20. Sinha Roy R., Yang P., Kodali S., Xiong Y., Kim R.M., Griffin P.R., Onishi H.R., Kohler J., Silver L.L., Chapman K. Direct interaction of a vancomycin derivative with bacterial enzymes involved in cell wall biosynthesis. Chem Biol. 8:2001;1095-1106.
21. Eggert U.S., Ruiz N., Falcone B.V., Branstrom A.A., Goldman R.C., Silhavy T.J., Kahne D. Genetic basis for activity differences between vancomycin and glycolipid derivatives of vancomycin. Science. 294:2001;361-364.
22. Paulsen I.T., Banerjei L., Myers G.S., Nelson K.E., Seshadri R., Read T.D., Fouts D.E., Eisen J.A., Gill S.R., Heidelberg J.F.et al. Role of mobile DNA in the evolution of vancomycin-resistant Enterococcus faecalis. Science. 299:2003;2071-2074 This paper described the genome sequence of vancomycin resistant E. faecalis and the surprising finding that approximately 25% of the sequence is derived from mobile DNA elements. This finding highlights the dramatic amount of genetic exchange in bacterial populations that has a major impact on the dissemination of resistance.
23. Wright G.D. Aminoglycoside-modifying enzymes. Curr Opin Microbiol. 2:1999;499-503.
24. Llano-Sotelo B., Azucena E.F. Jr., Kotra L.P., Mobashery S., Chow C.S. Aminoglycosides modified by resistance enzymes display diminished binding to the bacterial ribosomal aminoacyl-tRNA site. Chem Biol. 9:2002;455-463 The research described in this paper quantifies for the first time the impact of aminoglycoside modification on binding to the 16S rRNA target.
25. Perdersen L.C., Benning M.M., Holden H.M. Structural investigation of the antibiotic and ATP-binding sites in kanamycin nucleotidyltransferase. Biochemistry. 34:1995;13305-13311.
26. Hon W.C., McKay G.A., Thompson P.R., Sweet R.M., Yang D.S.C., Wright G.D., Berghuis A.M. Structure of an enzyme required for aminoglycoside resistance reveals homology to eukaryotic protein kinases. Cell. 89:1997;887-895.
27. Wolf E., Vassilev A., Makino Y., Sali A., Nakatani Y., Burley S.K. Crystal structure of a GCN5-related N-acetyltransferase: Serratia marcescens aminoglycoside 3-N-acetyltransferase. Cell. 94:1998;439-449.
28. Wybenga-Groot L., Draker Ka., Wright G.D., Berghuis A.M. Crystal structure of an aminoglycoside 6′-N-acetyltransferase:defiing the GCN5-related N-acetyltransferase superfamily fold. Structure. 7:1999;497-507.
29. Nurizzo D., Shewry S.C., Perlin M.H., Brown S.A., Dholakia J.N., Fuchs R.L., Deva T., Baker E.N., Smith C.A. The crystal structure of aminoglycoside-3′-phosphotransferase-IIa, an enzyme responsible for antibiotic resistance. J Mol Biol. 327:2003;491-506.
30. Vetting M.W., Hegde S.S., Javid-Majd F., Blanchard J.S., Roderick S.L. Aminoglycoside 2′-N-acetyltransferase from Mycobacterium tuberculosis in complex with coenzyme A and aminoglycoside substrates. Nat Struct Biol. 9:2002;653-658 The authors present the first structures of aminoglycosides bound in the active site of an aminoglycoside acetyltransferase.
31. Daigle D.M., McKay G.A., Thompson P.R., Wright G.D. Aminoglycoside antibiotic phosphotransferases are also serine protein kinases. Chem Biol. 6:1999;11-18.
32. Boehr D.D., Thompson P.R., Wright G.D. Molecular mechanism of aminoglycoside antibiotic kinase APH(3′)-IIIa: roles of conserved active site residues. J Biol Chem. 276:2001;23929-23936.
33. Thompson P.R., Boehr D.D., Berghuis A.M., Wright G.D. Mechanism of aminoglycoside antibiotic kinase APH(3′)-IIIa: role of the nucleotide positioning loop. Biochemistry. 41:2002;7001-7007.
34. Fong D.H., Berghuis A.M. Substrate promiscuity of an aminoglycoside antibiotic resistance enzyme via target mimicry. EMBO J. 21:2002;2323-2331 The authors present the first structures of aminoglycosides bound in the active site of an aminoglycoside kinase. They conclude that the antibiotics bind to the resistance enzymes in similar conformations as the ribosomal target.
35. Magnet S., Smith T.A., Zheng R., Nordmann P., Blanchard J.S. Aminoglycoside resistance resulting from tight drug binding to an altered aminoglycoside acetyltransferase. Antimicrob Agents Chemother. 47:2003;1577-1583.
36. Sucheck S.J., Wong A.L., Koeller K.M., Boehr D.D., Draker K.-a., Sears P., Wright G.D., Wong C.-H. Design of bifunctional antibiotics that target bacterial rRNA and inhibit resistance-causing enzymes. J Am Chem Soc. 122:2000;5230-5231.
37. Boehr D.D., Draker K., Koteva K., Bains M., Hancock R.E., Wright G.D. Broad-spectrum peptide inhibitors of aminoglycoside antibiotic resistance enzymes. Chem Biol. 10:2003;189-196 The authors describe the first inhibitory molecules that block both aminoglycoside kinase and acetyltransferase activity.
38. Carter A.P., Clemons W.M., Brodersen D.E., Morgan-Warren R.J., Wimberly B.T., Ramakrishnan V. Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics. Nature. 407:2000;340-348.
39. Haddad J., Kotra L.P., Llano-Sotelo B., Kim C., Azucena E.F. Jr., Liu M., Vakulenko S.B., Chow C.S., Mobashery S. Design of novel antibiotics that bind to the ribosomal acyltransfer site. J Am Chem Soc. 124:2002;3229-3237 First reported 'rational' design of aminoglycoside antibiotics.
40. Russell R.J., Murray J.B., Lentzen G., Haddad J., Mobashery S. The complex of a designer antibiotic with a model aminoacyl site of the 30S ribosomal subunit revealed by X-ray crystallography. J Am Chem Soc. 125:2003;3410-3411.
41. Yu L., Oost T.K., Schkeryantz J.M., Yang J., Janowick D., Fesik S.W. Discovery of aminoglycoside mimetics by NMR-based screening of Escherichia coli A-site RNA. J Am Chem Soc. 125:2003;4444-4450.
42. Simjee S., White D.G., Meng J., Wagner D.D., Qaiyumi S., Zhao S., Hayes J.R., McDermott P.F. Prevalence of streptogramin resistance genes among Enterococcus isolates recovered from retail meats in the Greater Washington DC area. J Antimicrob Chemother. 50:2002;877-882.
43. Simjee S., White D.G., Wagner D.D., Meng J., Qaiyumi S., Zhao S., McDermott P.F. Identification of vat(E) in Enterococcus faecalis isolates from retail poultry and its transferability to Enterococcus faecium. Antimicrob Agents Chemother. 46:2002;3823-3828.
44. McDonald L.C., Rossiter S., Mackinson C., Wang Y.Y., Johnson S., Sullivan M., Sokolow R., DeBess E., Gilbert L., Benson J.A.et al. Quinupristin-dalfopristin-resistant Enterococcus faecium on chicken and in human stool specimens. N Engl J Med. 345:2001;1155-1160.
45. Singh K.V., Weinstock G.M., Murray B.E. An Enterococcus faecalis ABC homologue (Lsa) is required for the resistance of this species to clindamycin and quinupristin-dalfopristin. Antimicrob Agents Chemother. 46:2002;1845-1850.
46. Sugantino M., Roderick S.L. Crystal structure of Vat(D): an acetyltransferase that inactivates streptogramin group A antibiotics. Biochemistry. 41:2002;2209-2216 This is the first structure of this class of antibiotic resistance enzyme that inactivates group A streptogramins, which have only been approved for human use in North America since 1999.
47. Weisblum B. Erythromycin resistance by ribosome modification. Antimicrob Agents Chemother. 39:1995;577-585.
48. Allignet J., Loncle V., Mazodier P., el Sohl N. Nucleotide sequence of a staphylococcal plasmid gene, vgb, encoding a hydrolase inactivating the B components of virginiamycin-like antibiotics. Plasmid. 20:1988;271-275.
49. Le Goffic F., Capmau M.L., Abbe J., Cerceau C., Dublanchet A., Duval J. Plasmid mediated pristinamycin resistance: PH 1A, a pristinamycin 1A hydrolase. Ann Microbiol (Paris). 128B:1977;471-474.
50. Mukhtar T.A., Koteva K.P., Hughes D.W., Wright G.D. Vgb from Staphylococcus aureus inactivates streptogramin B antibiotics by an elimination mechanism not hydrolysis. Biochemistry. 40:2001;8877-8886 The authors describe a surprising elimination mechanism for inactivation of the cyclic group b streptogramin depsipeptides, correcting the previous literature that indicated that these enzymes were hydrolases.
51. Douthwaite S., Hansen L.H., Mauvais P. Macrolide-ketolide inhibition of MLS-resistant ribosomes is improved by alternative drug interaction with domain II of 23S rRNA. Mol Microbiol. 36:2000;183-193.
52. Liu M., Douthwaite S. Activity of the ketolide telithromycin is refractory to Erm monomethylation of bacterial rRNA. Antimicrob Agents Chemother. 46:2002;1629-1633.
53. Bonnefoy A., Girard A.M., Agouridas C., Chantot J.F. Ketolides lack inducibility properties of MLS(B) resistance phenotype. J Antimicrob Chemother. 40:1997;85-90.
54. Clarebout G., Leclercq R. Fluorescence assay for studying the ability of macrolides to induce production of ribosomal methylase. Antimicrob Agents Chemother. 46:2002;2269-2272.